SAFETY AND EFFICACY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (mRCC): PRELIMINARY ASSESSMENT OF AN ITALIAN EXPANDED-ACCESS PROGRAM (EAP) WITH SUBPOPULATION ANALYSIS

Renal Cell ◽

Preliminary Assessment ◽

Safety And Efficacy ◽

Expanded Access ◽

Expanded Access Program ◽

696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.092 ◽

2021 ◽

Vol 32 ◽

pp. S709

Author(s):

S.E. Rebuzzi ◽

A. Signori ◽

M. Maruzzo ◽

G. Tortora ◽

L. Galli ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Expanded Access ◽

Expanded Access Program ◽

7148 POSTER Hyperglycemia and Hypercholesterolemia and Associated Outcomes of Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus in the Expanded-access Program REACT

European Journal of Cancer ◽

10.1016/s0959-8049(11)72063-9 ◽

2011 ◽

Vol 47 ◽

pp. S519 ◽

Cited By ~ 1

Author(s):

P. Bono ◽

D. Kim ◽

A. Panneerselvam ◽

V. Grünwald

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Expanded Access ◽

Expanded Access Program ◽

Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Annals of Oncology ◽

10.1093/annonc/mdx371.055 ◽

2017 ◽

Vol 28 ◽

pp. v319-v320

Author(s):

G. Procopio ◽

M. Prisciandaro ◽

R. Iacovelli ◽

M. Mancini ◽

G. Fornarini ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Real World ◽

Renal Cell ◽

Real World Data ◽

Safety And Efficacy ◽

World Data ◽

Expanded Access Program ◽

4503 ORAL Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71134-5 ◽

2007 ◽

Vol 5 (4) ◽

pp. 299 ◽

Cited By ~ 9

Author(s):

M. Gore ◽

C. Szczylik ◽

C. Porta ◽

S. Bracarda ◽

R. Hawkins ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Preliminary Assessment ◽

Safety And Efficacy ◽

Expanded Access

Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy

Annals of Oncology ◽

10.1093/annonc/mdx371.051 ◽

2017 ◽

Vol 28 ◽

pp. v318

Author(s):

R. Sabbatini ◽

L. Galli ◽

S. Pignata ◽

G. Lo Re ◽

F. Valcamonico ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Elderly Patients ◽

Cell Carcinoma ◽

Renal Cell ◽

Safety Data ◽

Efficacy And Safety ◽

Expanded Access ◽

Expanded Access Program ◽

REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis

Future Oncology ◽

10.2217/fon.15.241 ◽

2015 ◽

Vol 11 (21) ◽

pp. 2893-2903 ◽

Cited By ~ 2

Author(s):

Sergio Bracarda ◽

Sylvie Rottey ◽

Amit Bahl ◽

Christian Eichelberg ◽

Begoña Mellado ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Real World ◽

Renal Cell ◽

Real World Data ◽

World Data ◽

Expanded Access ◽

Expanded Access Program ◽

Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)

Annals of Oncology ◽

10.1093/annonc/mdx371.041 ◽

2017 ◽

Vol 28 ◽

pp. v314

Author(s):

S. Bracarda ◽

L. Galli ◽

M. Maruzzo ◽

G. Lo Re ◽

S. Buti ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Clinical Outcome ◽

Cell Carcinoma ◽

Renal Cell ◽

Expanded Access ◽

Expanded Access Program ◽

Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP)

Annals of Oncology ◽

10.1093/annonc/mdy283.102 ◽

2018 ◽

Vol 29 ◽

pp. viii317

Author(s):

A. Gomez de Liano Lista ◽

B. Venugopal ◽

K. Fife ◽

S. Symeonides ◽

N.S. Vasudev ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Expanded Access ◽

Expanded Access Program ◽

Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program

Future Oncology ◽

10.2217/fon-2017-0570 ◽

2018 ◽

Vol 14 (14) ◽

pp. 1347-1354 ◽

Cited By ~ 2

Author(s):

Sergio Bracarda ◽

Luca Galli ◽

Marco Maruzzo ◽

Giovanni Lo Re ◽

Sebastiano Buti ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Clinical Outcome ◽

Cell Carcinoma ◽

Renal Cell ◽

Expanded Access ◽

Expanded Access Program ◽

Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)

Annals of Oncology ◽

10.1093/annonc/mdy283.094 ◽

2018 ◽

Vol 29 ◽

pp. viii314

Author(s):

E. Verzoni ◽

G. Cartenì ◽

E. Cortesi ◽

F. Roila ◽

M.G. Vitale ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Events ◽

Cell Carcinoma ◽

Renal Cell ◽

Activity Data ◽

Expanded Access ◽

Expanded Access Program ◽